Myo1e overexpression in lung adenocarcinoma is associated with increased risk of mortality

Authors

Ignacio Jusue-Torres, Mayo Clinic, Rochester, MN
Richies Tiv, University of Illinois at Chicago College of Medicine, Chicago, IL
Julio C. Ricarte-Filho, Cancer Center, University of Illinois at Chicago, Chicago, IL
Apurva Mallisetty, University of Illinois at Chicago College of Medicine, Chicago, IL
Leglys Contreras-Vargas, University of Illinois at Chicago College of Medicine, Chicago, IL
Maria Jose Godoy-Calderon, Cancer Center, University of Illinois at Chicago, Chicago, IL
Karam Khaddour, University of Illinois at Chicago College of Medicine, Chicago, IL
Kathleen Kennedy, University of Illinois at Chicago College of Medicine, Chicago, IL
Klara Valyi-Nagy, University of Illinois at Chicago College of Medicine, Chicago, IL
Odile David, University of Illinois at Chicago College of Medicine, Chicago, IL
Martha Menchaca, University of Illinois at Chicago College of Medicine, Chicago, IL
Anastasia Kottorou, Medical School, University of Patras, Patras, Greece
Angelos Koutras, Medical School, University of Patras, Patras, Greece
Foteinos Dimitrakopoulos, Medical School, University of Patras, Patras, Greece
Khaled M. Abdelhady, Cancer Center, University of Illinois at Chicago, Chicago, IL
Malek Massad, University of Illinois at Chicago College of Medicine, Chicago, IL
Israel Rubinstein, Jesse Brown VA Medical Center, Chicago, IL
Lawrence Feldman, University of Illinois at Chicago College of Medicine, Chicago, IL
John Stewart, LSU Health Sciences Center - New Orleans
Takeshi Shimamura, Cancer Center, University of Illinois at Chicago, Chicago, IL
Ludmila Danilova, Johns Hopkins University School of Medicine, Baltimore, MD,
Alicia Hulbert, Cancer Center, University of Illinois at Chicago, Chicago, IL

Document Type

Article

Publication Date

3-13-2023

Publication Title

Scientific Reports

Abstract

This study aims to perform a comprehensive genomic analysis to assess the influence of overexpression of MYO1E in non-small cell lung carcinoma (NSCLC) and whether there are differences in survival and mortality risk in NSCLC patients depending on both DNA methylation and RNA expression of MYO1E. The DNA methylation probe cg13887966 was inversely correlated with MYO1E RNA expression in both LUAD and LUSC subpopulations showing that lower MYO1E RNA expression was associated with higher MYO1E DNA methylation. Late stages of lung cancer showed significantly lower MYO1E DNA methylation and significantly higher MYO1E RNA expression for LUAD but not for LUSC. Low DNA methylation as well as high RNA expression of MYO1E are associated with a shorter median survival time and an increased risk of mortality for LUAD, but not for LUSC. This study suggests that changes in MYO1E methylation and expression in LUAD patients may have an essential role in lung cancer's pathogenesis. It shows the utility of MYO1E DNA methylation and RNA expression in predicting survival for LUAD patients. Also, given the low normal expression of MYO1E in blood cells MYO1E DNA methylation has the potential to be used as circulating tumor marker in liquid biopsies.

First Page

4107

PubMed ID

36914720

Volume

13

Issue

1

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Recommended Citation

Jusue-Torres, Ignacio; Tiv, Richies; Ricarte-Filho, Julio C.; Mallisetty, Apurva; Contreras-Vargas, Leglys; Godoy-Calderon, Maria Jose; Khaddour, Karam; Kennedy, Kathleen; Valyi-Nagy, Klara; David, Odile; Menchaca, Martha; Kottorou, Anastasia; Koutras, Angelos; Dimitrakopoulos, Foteinos; Abdelhady, Khaled M.; Massad, Malek; Rubinstein, Israel; Feldman, Lawrence; Stewart, John; Shimamura, Takeshi; Danilova, Ludmila; and Hulbert, Alicia, "Myo1e overexpression in lung adenocarcinoma is associated with increased risk of mortality" (2023). School of Medicine Faculty Publications. 2033.
https://digitalscholar.lsuhsc.edu/som_facpubs/2033